• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

lois@unimelb.edu.au

Credentials


Position
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
ORCID

0000-0001-6137-9171

Prof Sherene Loi

Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology

832 Scholarly works
46 Projects

HIGHLIGHTS

  • 2026

    Journal article

    Single-fraction or multi-fraction stereotactic ablative body radiotherapy followed by atezolizumab in advanced triple-negative breast cancer: a randomized phase II trial
    DOI: 10.1038/s41467-026-75660-y
  • 2026

    Journal article

    Analysis of computational tumor-infiltrating lymphocytes in breast cancer from the results of the TIGER challenge
    DOI: 10.1038/s41467-026-72956-x
  • 2025

    Research grants (ARC, NHMRC, MRFF)

    Harnessing the Next Generation of Liquid Biopsy Assays for Clinical Translation in Breast Cancer
  • 2022

    Journal article

    Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice.
    DOI: 10.1038/s43018-022-00413-x
  • 2021

    Journal article

    Assessment of Ovarian Function in Phase 3 (Neo)adjuvant Breast Cancer Clinical Trials: A Systematic Evaluation.
    DOI: 10.1093/jnci/djab111
  • 2018

    Research Grant

    Capture: Circulating Tumour Dna Assessment of Pik3ca to Guide Treatment Response
  • 2018

    Research grants (other domestic)

    2018 NBCF Endowed Chair Program
Sherene Loi

RECENT SCHOLARLY WORKS

  • 2026

    Journal article

    Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse events
    DOI: 10.1038/s41523-026-00971-8
  • 2026

    Journal article

    A randomised phase II trial of neoadjuvant chemotherapy with or without concurrent aromatase inhibitor therapy in ER-positive breast cancer (ANZ1401 ELIMINATE).
    DOI: 10.1158/1078-0432.CCR-26-0501
  • 2026

    Journal article

    Overall survival with adjuvant ribociclib plus nonsteroidal aromatase inhibitor in patients with high-risk HR /HER2- early breast cancer: Six-year follow-up of the NATALEE trial.
    DOI: 10.1016/j.annonc.2026.10.1288
  • 2026

    Journal article

    The immunology of human breast cancer
    DOI: 10.1038/s41577-026-01307-0
  • 2026

    Journal article

    Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer☆
    DOI: 10.1016/j.annonc.2026.05.704
  • 2026

    Journal article

    Sovereignty and Survival: Understanding Lung Cancer Outcomes for Aboriginal and Torres Strait Islander People in Australia, a Case–Control Study
    DOI: 10.5694/mja2.70278
  • 2026

    Journal article

    Manual, digital, and AI tumour-infiltrating lymphocyte scoring: a secondary analysis of the APHINITY randomised trial
    DOI: 10.1016/S1470-2045(26)00247-0
  • 2026

    Journal article

    Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
    DOI: 10.1016/j.annonc.2026.05.707

Acknowledgement of Country

We acknowledge Aboriginal and Torres Strait Islander people as the Traditional Owners of the unceded lands on which we work, learn and live. We pay respect to Elders past, present and future, and acknowledge the importance of Indigenous knowledge in the Academy.

Read about our Indigenous priorities

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Campus locations  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia

facebookIconlinkedinIconinstagramIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy

CRICOS number: 00116K     ABN: 84 002 705 224